secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001664710-22-000042
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros CSO Lachey transitions to SVP Discovery at 75% time and reduced compensation
--------------------------------------------------------------------------------

- Jennifer Lachey's role changes from Chief Scientific Officer to Senior Vice President of Discovery, effective September 1, 2022.
- Base salary and unvested option shares reduced to 75% of prior levels; no longer eligible for severance.
- Change was at Dr. Lachey's request; she remains employed by the Company.
- No longer deemed an 'officer' or 'executive officer' under SEC rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471022000042/0001664710-22-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471022000042/kros-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001664710-22-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer